Opus Genetics (IRD) Income from Continuing Operations (2010 - 2026)
Opus Genetics' (IRD) quarterly Income from Continuing Operations came in at 65535000.0 in Q1 2026, down 699.79% year-on-year from 10926278.1 in Q1 2025, and down 972.76% on a QoQ basis from 6109000.0 in Q4 2025.
Opus Genetics (IRD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of Income from Continuing Operations data on file, last reported at 65535000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 699.79% year-over-year to 65535000.0 in Q1 2026; TTM through Mar 2026 was 96518000.0, a 64.65% decrease from a year earlier, with the FY2025 full-year figure at 39177000.0, up 31.9% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 65535000.0, down from 6109000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for IRD reached as high as 33941000.0 in Q4 2022 and fell as low as 65535000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 9078941.18 across 5 years, with a median of 6595000.0 in 2022.
- Across the five-year window, Income from Continuing Operations soared 637.64% in 2022 and slumped 699.79% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 33941000.0 in 2022, then slumped by 114.13% to 4795000.0 in 2023, then slumped by 632.74% to 35135000.0 in 2024, then soared by 82.61% to 6109000.0 in 2025, then plunged by 972.76% to 65535000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 65535000.0 in Q1 2026, 6109000.0 in Q4 2025, and 17454000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Opus Genetics | 3.27 Mn | -56.73 Mn | - | -65.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.54 Mn |
| Dec 31, 2025 | -6.11 Mn |
| Sep 30, 2025 | -17.45 Mn |
| Jun 30, 2025 | -7.42 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -35.14 Mn |
| Sep 30, 2024 | -7.53 Mn |
| Jun 30, 2024 | -7.77 Mn |
| Mar 31, 2024 | -7.11 Mn |
| Dec 31, 2023 | -4.80 Mn |
| Sep 30, 2023 | 5.56 Mn |
| Jun 30, 2023 | -4.96 Mn |
| Mar 31, 2023 | -5.79 Mn |
| Dec 31, 2022 | 33.94 Mn |
| Sep 30, 2022 | -4.53 Mn |
| Jun 30, 2022 | -4.93 Mn |
| Mar 31, 2022 | -6.60 Mn |
| Dec 31, 2021 | -6.31 Mn |
| Sep 30, 2021 | -4.23 Mn |
| Jun 30, 2021 | -7.14 Mn |